...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: I'll believe

"Does this make a little sense or am I way off base?"

With such an array of BP partners, Zenith has to be on the right track to success. And they are paying the bills.

Pfizer, Merck, AstraZeneca, Bristol Myers Squibb, Astellas, Lilly, GlaxoSmithKline, Newsoara, Dana-Farber, UCSF, University of Texas/MD Anderson Cancer Centre, & the University of Pittsburgh.

And to think this stock is only 20cents US. Truly unbelievable!!

fuzzy there is no need to wait to back that thing, right up. :) ....... Right Temsamany?

 

Koo 

Share
New Message
Please login to post a reply